Oral altretamine used as salvage therapy in recurrent ovarian cancer.

Article Details

Citation
Copy to clipboard

Chan JK, Loizzi V, Manetta A, Berman ML

Oral altretamine used as salvage therapy in recurrent ovarian cancer.

Gynecol Oncol. 2004 Jan;92(1):368-71.

PubMed ID
14751188 [ View in PubMed
]
Abstract

BACKGROUND: Altretamine has reported efficacy in the treatment of recurrent ovarian cancer following platinum-based therapy. This report presents the cases of two long-term survivors with recurrent ovarian cancer given oral altretamine. CASES: Two patients diagnosed with stage IIIC ovarian cancer underwent optimal cytoreductive surgery. Both women were subsequently treated with platinum-based chemotherapy. One had persistent cancer documented 2 months post therapy, while the other was disease-free for 22 months before recurring. Both received altretamine in a salvage setting. Each of these women achieved a prolonged response to third-line altretamine therapy, and one of whom was disease-free for 4 years and the other remains disease-free over 7 years following initiation of salvage therapy. CONCLUSION: Outpatient-administered oral altretamine can provide a prolonged disease-free interval with minimal toxicity.

DrugBank Data that Cites this Article

Drugs